Recombinant Human VSTM2A Fc Chimera Avi-tag Protein, CF

When Human VSTM2A Antibody (MAB100371) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human VSTM2A Fc Chimera Avi-tag (Catalog # AV10704) binds with an ED50 of 1.00-8.00 ng/mL

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human VSTM2A Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its ability to inhibit anti-CD3 antibody induced IL-2 or IFN-gamma secretion by human T cells. The ED₅₀ for this effect is 1.00-10.0 μg/mL Measured by its binding ability in a functional ELISA. When Human VSTM2A Antibody (Catalog # MAB100371) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human VSTM2A Fc Chimera Avi-tag (Catalog # AV10704) binds with an ED₅₀ of 1.00-8.00 ng/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human VSTM2A protein
  

  Human VSTM2A (Ser25-Phe244) Accession # NP_001304772.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: NP_001304772.1
• N-terminal Sequence: Ser25
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 53 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 62-75 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human VSTM2A Fc Chimera Avi-tag Protein, CF

• MGC33530
• V-set and transmembrane domain containing 2
• V-set and transmembrane domain containing 2A
• V-set and transmembrane domain-containing protein 2A
• VSTM2
• VSTM2A

Background

V-set and transmembrane domain-containing protein 2A (VSTM2A) is a secreted glycoprotein that is a member of the immunoglobulin superfamily (1). The VSTM family consists of 8 family members, each containing an immunoglobulin V-set (IgV) domain in the extracellular domain (ECD). In addition to the single IgV domain, VSTM2A contains two N-glycosylation sites in the ECD that are critical for its secretion, but not for activity (2). In humans, two isoforms exist due to alternative splicing, varying in the C-terminal residues. The mature ECD of human VSTM2A, isoform 2 shares 80% amino acid sequence identity with mouse and rat VSTM2A isoform 2. VSTM2A is expressed during adipocyte development and its over-expression promotes adipogenesis (1). VSTM2A promotes regulation and commitment of white and brown preadipocytes by increasing gene expression of the transcription factor PPARG in a BMP4-dependent signaling pathway (1, 2). VSTM2A is highly expressed in the brain but the role of VSTM2A in neuronal and brain development remain uncharacterized (3). VSTM2A is a critical tumor suppressor in colorectal carcinogenesis and a novel antagonist of Wnt signaling receptor LRP6, and might serve as a new prognostic marker for colorectal cancer patients (4). Our in house data show that VSTM2A inhibits the human T cell activation, including anti-CD3 induced IL-2 and IFN-gamma secretion, and T cell proliferation. Our Avi-tag Biotinylated VSTM2A features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Secco, B. et al. (2017) Cell Rep. 18:93.
2. Berry, D.C. et al. (2013) Development. 140:3939.
3. Pandey, A.K. et al. (2014) PloS One. 9:e88889.
   
4. Zhang, D. et al. (2019) Theranostics. 9:6517.

Bioinformatics

• Uniprot:
  • NP_001304772.1()